Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

about

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories

P2860

Q54214603-A3BF5C42-E462-4E28-BB6B-4FFF0092E3A7 Q58701180-EEF798D6-25BF-43B3-9373-A682823B1323

P2860

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

Item

http://www.wikidata.org/entity/Q50094753

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Isavuconazole susceptibility o ...... t isolates with elevated MICs.

@en

type

Item

label

Isavuconazole susceptibility o ...... t isolates with elevated MICs.

@en

prefLabel

Isavuconazole susceptibility o ...... t isolates with elevated MICs.

@en

P1476

Isavuconazole susceptibility o ...... at isolates with elevated MICs

@en

P2093

Jacques F Meis

http://www.w3.org/2001/XMLSchema#string

Jan Zoll

http://www.w3.org/2001/XMLSchema#string

Johan W Mouton

http://www.w3.org/2001/XMLSchema#string

Roeland E Wasmann

http://www.w3.org/2001/XMLSchema#string

Roger J M Brüggemann

http://www.w3.org/2001/XMLSchema#string

Willem J G Melchers

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health

Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?

Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

EUCAST testing of Isavuconazole susceptibility in Aspergillus: comparison of results for Inoculum standardization using Conidium counting versus optical density.

Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study

Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model

Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature.

Current approaches to diagnosis and treatment of invasive aspergillosis.

Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis.

P304

134-142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKX354

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jochem B Buil

Paul E. Verweij

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29048485

http://www.w3.org/2001/XMLSchema#string

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

about

P2860

P2860

Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698